About the Journal

  The Journal of Blood and Biotherapy publishes high-quality research to advance science and innovation in hematology, transfusion medicine, and biotherapeutics. With a core commitment to fostering interdisciplinary collaboration, it brings together researchers, clinicians, and industry partners to solve key problems in blood disorders, cellular therapies, and biological treatments. A key focus is on translational research, ensuring that scientific discoveries are effectively translated into clinical applications that improve patient care globally.

    The Journal of Blood and Biotherapy is an international publication that welcomes submissions from researchers worldwide. It publishes four issues per year, covering a wide spectrum of content including original research, reviews, case reports, short communications, letters to the editor, and more.

    The journal encompasses a wide range of topics, including but not limited to:
 
  1. Hematology and Blood Disorders
     
    • Pathophysiology, diagnosis, and therapeutic strategies for anemia, hemoglobinopathies, coagulation disorders, leukemia, lymphoma, and myeloma.
     
    • Recent advances in hematopoietic stem cell transplantation and regenerative medicine for hematologic conditions.
     
  2. Biotherapies and Cellular Therapies
     
    • Development and clinical applications of CAR-T cells, gene therapy, and engineered immune cell products.
     
    • Translational applications of CRISPR-based technologies, RNA therapeutics, and viral vectors in hematologic diseases.
     
  3. Transfusion Medicine
     
    • Safety of blood products, innovations in storage and preservation, and personalized transfusion strategies.
     
    • Management of transfusion-related adverse events and alloimmunization prevention.
     
  4. Immunotherapy and Immunohematology
     
    • Immune checkpoint inhibitors, monoclonal antibodies, and therapeutic vaccine development targeting hematologic malignancies.
     
    • Mechanisms of immune tolerance and rejection in hematopoietic stem cell transplantation.
     
  5. Biopharmaceuticals and Regulatory Science
     
    • Preclinical and clinical development of biologic agents (e.g., recombinant proteins, biosimilars, and novel biologics).
     
    • Regulatory frameworks, ethical considerations, and commercialization pathways for hematology-focused biologics.
     
  6. Emerging Technologies
     
    • AI-driven diagnostic tools, biomarker discovery platforms, and clinical applications of liquid biopsy in blood diseases.
     
    • Microfluidic devices and nanotechnology-enabled tools for real-time monitoring and management of hematologic disorders.